AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02031081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
Study NCT02031081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
Study NCT01376570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-reinforcing contingency management intervention
Description: The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
Study NCT01376570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Performance Feedback intervention
Description: Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
Study NCT02466074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: see arm description
Study NCT02999854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depleted HSCT from a related, haploidentical donor
Description: T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
Study NCT01161433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtually delivered spirometry quality improvement program
Description: Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system.
Study NCT02999854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-cell replete HSCT from a related, haploidentical donor
Description: T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
Study NCT03427528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers and Babies (FAB)
Description: The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
Study NCT01847157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current.
Study NCT01847157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermis anesthesia
Description: 15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Study NCT03427528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB 1-on-1 plus TXT
Description: Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
Study NCT02912832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBDx
Description: The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
Study NCT04615429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Administration of one single dose of allogenic Mesenchymal stromal cells
Study NCT03512782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARDIOENF
Description: The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
Study NCT01847157 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham anesthesia
Description: 15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Study NCT01847157 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repeated passive movement
Description: Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes.
Study NCT01847157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated passive movement
Description: Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes.
Study NCT02466074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study NCT01847157 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
Study NCT04081311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparing interdental floss to water flosser around dental implants
Description: to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
Study NCT04081311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comparing interdental floss to water flosser around dental implants
Description: to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
Study NCT01744054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MR
Study NCT01744054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Study NCT05058443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: denosumab subcutaneously every 6 months (Q6M)
Study NCT00536874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
Study NCT05058443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo subcutaneously every 6 months (Q6M)
Study NCT00848367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy
Description: This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
Study NCT04212104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watch a mukbang
Description: watch the dim sum mukbang
Study NCT04212104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: watch a non-food video
Description: watch the Big Bang Theory video
Study NCT01269424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MGMTP140K-encoding retroviral vector
Study NCT00536874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
Study NCT00536874 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT04615429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (solution identical to experimental treatment, without the MSC)
Study NCT00959829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music and message
Description: Experimental group: music and message Control group: silence
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily
Study NCT01526928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily
Study NCT01365715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography and preoperative embolization
Description: Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
Study NCT01365715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriography
Description: Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
Study NCT02411266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ischemic conditioning group
Description: application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
Study NCT02411266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemic conditioning group
Description: application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
Study NCT00836953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (Pediatric formulation)
Description: 0.25 mL, Intramuscular
Study NCT02680366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen/ABMNC scaffold
Description: The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
Study NCT00536874 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Study NCT00536874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT02680366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter balloon
Description: The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
Study NCT00642824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
Study NCT00642824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
Study NCT03021707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight® Ultraviolet Femtosecond (FS) Laser System
Description: Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
Study NCT00536874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00536874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00536874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00110071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT03021707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Assisted Lenticular Extraction
Description: Used for refractive error correction
Study NCT03656146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Insecurity Screening Tablet
Description: The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
Study NCT03656146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Insecurity Screening Verbal
Description: The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
Study NCT02150785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Study NCT00110071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
Study NCT00110071 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 tositumomab
Description: Given IV (dosimetric dose) or via central line (therapeutic dose)
Study NCT00997607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola vaccine
Description: 4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
Study NCT00997607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marburg vaccine
Description: 4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
Study NCT00997607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: 4 mg of saline injection delivered at Weeks 0, 4, and 8
Study NCT02033824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM
Description: A piece of dHACM placed over any dural defect or dural closure during craniectomy.
Study NCT02033824 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Craniectomy
Description: Removal of the skull flap followed by closure techniques per current SOC.
Study NCT02033824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniectomy
Description: Removal of the skull flap followed by closure techniques per current SOC.
Study NCT02908945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
Study NCT02908945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSENSE monitor
Description: NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
Study NCT00110071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00110071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00110071 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT02908945 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroSENSE monitor
Description: NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
Study NCT04237909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection into at least one ovary
Description: The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
Study NCT00894218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty
Description: Hip or knee arthroplasty
Study NCT06762509 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Local injection of botulinum toxin type A was given at the time of enrollment
Study NCT01661231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astron/Pulsar-18 stent
Description: Peripheral Vascular Intervention
Study NCT00490126 — intervention group
Intervention type: OTHER
Intervention: Laparoscopic Surgery Data Collection
Description: Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.